Table 2.
Training set | Validation set | ||||
---|---|---|---|---|---|
Marker | Cut-off | Sensitivity (%) | Specificity (%) | Sensitivity (%) | Specificity (%) |
CA19-9 (≥ 55 U/ml) | |||||
55 | 91 | 63 | 96 | ||
THBS2 (≥ 42 ng/ml) | |||||
41 | 96 | 50 | 96 | ||
cfDNA (ng/ml) | |||||
5 FP | 12.4 | 86 | 70 | 80 | 79 |
4 FP | 16.0 | 68 | 87 | 70 | 96 |
3 FP | 16.2 | 68 | 87 | 70 | 96 |
2 FP | 18.8 | 65 | 65 | 57 | 96 |
1 FP | 19.0 | 45 | 91 | 57 | 96 |
0 FP | 28.0 | 32 | 100 | 43 | 96 |
CA19-9 (≥ 55 U/ml) + THBS2 (≥ 42 ng/ml) | |||||
73 | 91 | 80 | 96 | ||
CA19-9 (≥ 55 U/ml) + THBS2 (≥ 42 ng/ml) + cfDNA (ng/ml) | |||||
5 FP | 12.4 | 86 | 78 | 93 | 92 |
4 FP | 16.0 | 86 | 83 | 87 | 92 |
3 FP | 16.2 | 86 | 87 | 87 | 92 |
2 FP | 18.8 | 73 | 91 | 80 | 92 |
1 FP | 19.0 | 73 | 96 | 80 | 92 |
0 FP | 28.0 | 41 | 96 | 50 | 96 |
FP=false-positives